Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema [PDF]
, 2014 Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and other anti ...
Alkabes, M, Dutra-Medeiros, M, Nucci, P
core +1 more source
Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema [PDF]
Ophthalmology and Therapy, 2016 Patients with diabetic macular edema (DME), a chronic, vision-limiting condition, may be insufficiently responsive to standard-of-care anti-vascular endothelial growth factor (VEGF) and/or laser therapies. One approved treatment for such patients is 0.2 μg/day fluocinolone acetonide (FAc) sustained-release implant; however, data are limited for ...
Elaraoud, Ibrahim +2 more
+8 more sources
Corticosteroids for diabetic macular edema
Taiwan Journal of Ophthalmology, 2019 Diabetic macular edema (DME) is a chronic condition with a multifactorial pathogenesis. Vascular endothelial growth factor (VEGF) and several inflammatory mediators are upregulated in eyes with DME.
Jorge Chawan-Saad +3 more
doaj +1 more source
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience [PDF]
, 2021 We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME)
Agodi A. +14 more
core +1 more source
Diffusion through the ex vivo vitreal body - bovine, porcine, and ovine models are poor surrogates for the human vitreous [PDF]
, 2018 © 2018 The Authors. Published by Elsevier B.V.The human vitreous humour is a complex gel structure whose composition and physical properties can vary considerably from person to person and also change with age. To date, the viscoelastic properties of the
Brown, Marc +4 more
core +4 more sources
Local delivery of corticosteroids in clinical ophthalmology: A review
Clinical &Experimental Ophthalmology, Volume 48, Issue 3, Page 366-401, April 2020., 2020 Abstract Locally administered steroids have a long history in ophthalmology for the treatment of inflammatory conditions. Anterior segment conditions tend to be treated with topical steroids whilst posterior segment conditions generally require periocular, intravitreal or systemic administration for penetration.
Adrian T. Fung +12 more
wiley +1 more source
Sustained-release steroids for the treatment of diabetic macular edema. [PDF]
, 2015 Glucocorticoids have been used for decades in the treatment of ocular disorders via topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of action on ocular tissues remain imperfectly understood.
Behar-Cohen, F., Daruich, A., Matet, A.
core +1 more source
Erratum: Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes [PDF]
Eye, 2016 Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised ...
A, Kumar +4 more
openaire +4 more sources
Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema [PDF]
, 2016 Purpose: To compare intravitreal bevacizumab monotherapy with intravitreal dexamethasone delayed delivery system monotherapy for persistent diabetic macular edema.
Bleau, Laura +3 more
core +1 more source
Case Reports in Ophthalmology, 2016 Importance: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 µg/day fluocinolone acetonide, FAc) despite suboptimal responses to ranibizumab.
Hibba Quhill, Fahd Quhill
doaj +1 more source